Literature DB >> 28294292

Q-TWiST: What really matters to the cancer patient?

Olga Husson1,2, Robin L Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28294292     DOI： 10.1002/cncr.30662

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer?

Authors:  Y J Ko; M Abdelsalam; P Kavan; H Lim; P A Tang; M Vincent; R Wong; M Kish; S Gill
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

2.  A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

Authors:  Michelle K Wilson; Michael L Friedlander; Florence Joly; Amit M Oza
Journal:  Oncologist       Date:  2017-11-08

3.  A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).

Authors:  Ruchitbhai Shah; Marc Botteman; Caitlyn T Solem; Linlin Luo; Justin Doan; David Cella; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2019-05-31       Impact factor: 2.872

4.  A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.

Authors:  Caitlyn T Solem; Timothy J Bell; Youngmin Kwon; Joseph C Cappelleri; Courtney Johnson; Helen Bhattacharyya; Caroline J Hoang; Jorge E Cortes
Journal:  Cancer       Date:  2020-07-22       Impact factor: 6.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.